Abliva AB
About:
Abliva develops medicines for the treatment of primary mitochondrial diseases.
Website: https://abliva.com/
Top Investors: IP Group, Vinnova, U.S. Department of Defense, Hadean Ventures, Congressionally Directed Medical Research Programs
Description:
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
$40.4M
Less than $1M
Lund, Skane Lan, Sweden
2000-01-01
info(AT)abliva.com
Eskil Elmér
1-10
2022-05-31
Public
© 2025 bioDAO.ai